<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) is a highly aggressive B cell <z:hpo ids='HP_0002664'>neoplasm</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Although intensive polychemotherapy regimens have proven very effective, they are associated with significant toxicities </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, more rational therapies that selectively target the molecular abnormalities of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> are needed </plain></SENT>
<SENT sid="3" pm="."><plain>Recent data suggest that the tyrosine kinase SRC could represent a therapeutic target for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>We found that new pyrazolo[3,4-d]<z:chebi fb="0" ids="16898">pyrimidine</z:chebi> SRC inhibitors exerted a significant cytotoxic effect and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> on two <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cell lines, as determined by MTS assays, cytofluorimetric analyses and caspase 3 assay </plain></SENT>
<SENT sid="5" pm="."><plain>Notably, our SRC inhibitors proved to be more effective than the well-known SRC inhibitor PP2 [4-amino-5-(4-chlorophenyl)-7-(dimethylethyl)pyrazolo[3,4-d]<z:chebi fb="0" ids="16898">pyrimidine</z:chebi>] in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Moreover, our small molecules induced a G 2/M arrest in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> cells through a possible new mechanism, whereby SRC inhibition hinders an AKT-WEE1-cyclin-dependent kinase 1 (CDK1) axis, leading to inhibition of CDK1, the main trigger of entry into mitosis </plain></SENT>
<SENT sid="7" pm="."><plain>By using a small-molecule inhibitor of WEE1, a crucial CDK1 negative regulator, we were able to shift the balance toward <z:mpath ids='MPATH_3'>apoptosis</z:mpath> rather than <z:mpath ids='MPATH_73'>growth arrest</z:mpath> and enhance the efficacy of the SRC inhibitors, suggesting a possible use of these selective drugs in combination for a safe and efficient treatment of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e> </plain></SENT>
</text></document>